Stereotaxis and ADAS 3D Combine Robotic Precision and Advanced Preoperative Substrate Mapping to Treat Cardiac Arrhythmias
Stereotaxis (NYSE American: STXS) and ADAS 3D Medical SL
today announced the first patients have been successfully treated with
the integration of ADAS 3D’s advanced preoperative substrate mapping and
Stereotaxis’ Robotic Magnetic Navigation technologies.
ADAS 3D MEDICAL SL, a company based in Barcelona, is the recent offspring of the electrophysiology business of Galgo Medical SL (Barcelona, Spain) in partnership with Circle Cardiovascular Imaging Inc. (Calgary, Canada). Its mission is to expand accessibility and use of Cardiac Imaging (MRI and CT) to electrophysiology procedures such as Atrial Fibrillation and Ventricular Tachycardia ablations. ADAS 3D established itself as an early innovator in this field by introducing software intended for the identification of arrhythmia substrate and guidance of ablation treatment, for safer and more efficient procedures. For more information, please visit www.adas3d.com.
“Life-threatening arrhythmias are common in patients
that have suffered a myocardial infarction. Cardiac ablation can help
these patients, but often require extensive searching to find targets
and widespread ablation to ensure all problematic tissue has been
addressed,” said Prof. Pedro Adragao. “ADAS 3D supports rapid and
precise identification of such tissue. We have long recognized the
clinical value of Robotic Magnetic Navigation to treat patients with
precision and safety. The integration of both technologies should result
in more effective, rapid, and safe procedures for patients.”ADAS 3D
helps identify possible sources of dangerous irregular heartbeats and
provides a map to guide physicians in delivering treatment. The software
uses preoperative cardiac MRI to generate detailed three-dimensional
cardiac models that identify arrhythmia substrate and characterize
cardiac tissue. The identification of fibrotic cardiac tissue and
channels of electrical conduction is particularly valuable for planning
Ventricular Tachycardia ablation procedures. It can also be used during
Atrial Fibrillation procedures to define the shape of the Left Atrium
and its fibrosis distribution, quantifying it and improving guidance
due to better identification of ablation targets. The latest version of
Stereotaxis software, recently cleared for use in Europe and by the FDA,
utilizes a software interface that integrates ADAS 3D’s images and
allows physicians to utilize them to guide therapy during robotic
cardiac ablation procedures. The first integrated procedures were
successfully conducted by Prof. Pedro Adragao of Hospital da Luz in
Lisbon, Portugal.
“Combining our technology with Stereotaxis is an
exciting opportunity that we believe will positively impact the field of
Electrophysiology,” said Luis Serra, President of ADAS 3D Medical. “The
ability to translate combined MRI and CT images into 3D coordinates of
the patient’s heart and then use robotics for precision navigation of
therapy should provide more reproducible treatment during cardiac
ablation. We hope this will benefit health care professionals and their
patients.”
“Stereotaxis is committed to advancing a robust open
ecosystem where physicians and patients benefit from the broad
integration of procedure data,” said David Fischel, CEO of Stereotaxis.
“We are excited to be working with ADAS 3D. The combination of advanced
diagnostic imaging with robotic navigation is a step forward in the
digitization of electrophysiology.”
About ADAS 3DADAS 3D MEDICAL SL, a company based in Barcelona, is the recent offspring of the electrophysiology business of Galgo Medical SL (Barcelona, Spain) in partnership with Circle Cardiovascular Imaging Inc. (Calgary, Canada). Its mission is to expand accessibility and use of Cardiac Imaging (MRI and CT) to electrophysiology procedures such as Atrial Fibrillation and Ventricular Tachycardia ablations. ADAS 3D established itself as an early innovator in this field by introducing software intended for the identification of arrhythmia substrate and guidance of ablation treatment, for safer and more efficient procedures. For more information, please visit www.adas3d.com.
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ robotic technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ robotic technology has received various regulatory clearances in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and uncertainties
that could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability
to raise additional capital on a timely basis and on terms that are
acceptable, its ability to continue to manage expenses and cash burn
rate at sustainable levels, its ability to continue to work with lenders
to extend, repay or refinance indebtedness, or to obtain additional
financing, in either case on acceptable terms, continued acceptance of
the Company's products in the marketplace, the effect of global economic
conditions on the ability and willingness of customers to purchase its
systems and the timing of such purchases, competitive factors, changes
resulting from healthcare reform in the United States, including changes
in government reimbursement procedures, dependence upon third-party
vendors, timing of regulatory approvals, and other risks discussed in
the Company's periodic and other filings with the Securities and Exchange Commission.
By making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after the
date of this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other commitments
in any particular period or at all because some of these purchase orders
and other commitments are subject to contingencies that are outside of
the Company's control. In addition, these orders and commitments may be
revised, modified, delayed or canceled, either by their express terms,
as a result of negotiations, or by overall project changes or delays.
Comments
Post a Comment